Direxion S&P Biotech Bear 3X

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

LABD

SBIO

ARKG

Wave Life Sciences Ltd. reported a significant decline in Q4 2025 sales to $17.24 million, with a net loss of $53.18 million, compared to a profit last year. Despite these losses, the company is pursuing an accelerated approval pathway for its drug WVE-006 for alpha-1 antitrypsin deficiency, which may enhance its investment narrative. Analysts express concerns over liquidity and potential revenue declines, while the company projects $177.5 million in revenue by 2028, suggesting a fair value of $33.50, indicating a 155% upside from current prices.

Simplywall

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares Biotechnology ETF

SPDR Pharmac

Wave Life Sciences

iShares US Pharma

ALPS Medical Breakthrough

Bioshares Biotech Clinical Trials Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VG Health

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed

ABBV

IBBQ

Gabelli Funds LLC has reduced its stake in AbbVie Inc. (NYSE:ABBV) by 6.2%, now holding 100,963 shares valued at $23.38 million. Other institutional investors have also adjusted their positions in AbbVie. Analysts have mixed ratings on the stock, with a consensus price target of $253.15. AbbVie recently reported earnings of $2.71 per share, exceeding estimates, and declared a quarterly dividend of $1.73 per share, yielding 3.0%. The stock is currently trading at $230.41, down 0.8%.

Market Beat

Abbvie

Invesco Nasdaq Biotechnology ETF

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV

ARDX

Ardelyx (ARDX) is currently priced at approximately $6.19, reflecting a 5.5% decline over the past week and a 16.1% decline over the last month. Despite a 16.8% return over the past year, the stock is considered undervalued by 89.5% based on a Discounted Cash Flow (DCF) analysis, which estimates an intrinsic value of $58.79 per share. Additionally, Ardelyx's Price-to-Sales (P/S) ratio of 3.73x is below industry averages, indicating further undervaluation. Investors are encouraged to consider their own narratives regarding the company's future performance.

Ardelyx

Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility

Black Diamond (BDI) Signals Growth Despite Near-Term Lumps

Tip Ranks

Black Diamond Therapeutics

Black Diamond (BDI) Signals Growth Despite Near-Term Lumps

At the CRT annual conference, Dr. Christopher Chieh Yang Koo presented the first US Medicare outcomes data for angiography-derived physiology (ADP) from over 4,000 CathWorks FFRangio patients. The study shows that ADP demonstrates similar clinical outcomes to invasive pressure wire-guided PCI through two years, with a comparable cumulative incidence of major adverse cardiac events (MACE). The adoption of ADP has grown significantly, and experts believe it may become the new standard of care for physiology in cardiovascular disease diagnosis and treatment.

prnewswire

Medtronic

iShares US Medical Devices

SPDR S&P Health Equip

16:00 ETLate-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through 2 Years

SLNO

Robbins Geller Rudman & Dowd LLP announces a class action lawsuit for investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO) who suffered losses between March 26, 2025, and November 4, 2025. The lawsuit alleges that Soleno and its executives violated the Securities Exchange Act by failing to disclose safety concerns related to their product, DCCR, leading to significant stock price declines. Investors can seek appointment as lead plaintiff until May 5, 2026. Robbins Geller specializes in securities fraud litigation and represents the plaintiffs in this case.

Soleno Therapeutics

13:10 ETINVESTOR ALERT: Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law

Eli Lilly is currently a leading player in the GLP-1 drug market with its successful products, Mounjaro and Zepbound. However, the stock is highly valued with a P/E ratio of 44, raising concerns about future growth amid competition and potential patent expirations. Analysts suggest that while Eli Lilly's current success is notable, the company's long-term prospects may be uncertain, and investors should consider other stocks that may offer better returns.

nasdaq

Eli Lilly

Direxion Daily LLY Bear 1X Shares

Defiance Daily Target 2X Short LLY ETF

Direxion Daily LLY Bull 2X Shares

Defiance Daily Target 2X Long LLY ETF

Where Will Eli Lilly Stock Be in 10 Years?

PHAT

GW&K Investment Management LLC increased its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 9.1% in Q3, owning 1,144,330 shares valued at approximately $13.47 million. Other institutional investors also raised their holdings, with Frazier Life Sciences Management L.P. increasing by 23.3%. Phathom's stock is currently down 0.7%, trading at $10.67, with a market cap of $840.80 million. Analysts have mixed ratings, with a consensus price target of $22.25. Phathom focuses on developing treatments for gastrointestinal diseases, with its lead asset being vonoprazan.

Phathom Pharmaceuticals

GW&K Investment Management LLC Has $13.47 Million Stock Position in Phathom Pharmaceuticals, Inc. $PHAT

ATYR

Atyr Pharma Inc. (ATYR) is at risk of delisting from Nasdaq after receiving a deficiency notice for trading below the $1.00 minimum bid price for 30 consecutive business days. If compliance is not regained, possibly through a reverse stock split, shares may move to over-the-counter markets, leading to reduced liquidity and increased volatility. This situation could hinder access to capital and diminish investor confidence, negatively impacting the company's long-term prospects. The average stock price target for ATYR is $1.00, suggesting a 21.36% upside potential.

ATYR Pharma

Atyr Pharma Faces Nasdaq Delisting Risk After Minimum Bid Price Violation

Scholar Rock Holding Corporation reported a net loss of $90.97 million for Q4 and $377.94 million for the full year 2025. The company filed a $269.23 million shelf registration for over 6 million common shares related to an ESOP offering. Scholar Rock is focusing on the launch of apitegromab and plans to resubmit its Biologics License Application after addressing FDA concerns. The investment narrative hinges on the successful launch and regulatory approval of apitegromab, with projected revenues of $398.1 million by 2029, despite rising losses and heavy pre-launch investments.

Scholar Rock

Will Scholar Rock’s Rising Losses, Shelf Filing and Apitegromab Push Change Scholar Rock Holding's (SRRK) Narrative

FRDU

Regencell Bioscience, an early-stage bioscience company focused on traditional Chinese medicine, has a market cap of nearly $12 billion and a staggering 21,000% stock increase over the past year. However, it lacks a marketable product and revenue, making it a high-risk investment. Analysts recommend avoiding Regencell due to its uncertain future and suggest considering more established companies like Pfizer instead. The Motley Fool's Stock Advisor has identified ten better investment options than Regencell.

Regencell Bioscience

Direxion Daily F Bull 2X ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

GraniteShares 2x Long BULL Daily ETF

Here's Why I Wouldn't Touch Regencell Bioscience With a 10‑Foot Pole Right Now

OCGN

Shares of Ocugen Inc. (OCGN) fell 7.47% to $1.61 on Friday, marking the second consecutive day of losses amid a broader market decline, with the S&P 500 down 1.33% and the Dow Jones down 0.95%. The stock is now 19.50% below its 52-week high of $2.00 reached on March 4th, with trading volume at 5.6 million, slightly above its 50-day average of 5.5 million.

Dow Jones

Ocugen

Ocugen Inc. Stock Falls Friday, Underperforms Market

Illumina Inc. (ILMN) shares fell 2.82% to $124.62 on Friday, marking the fifth consecutive day of losses amid a broader market decline, with the S&P 500 down 1.33%. The stock is currently 19.87% below its 52-week high of $155.53. Competitors Labcorp, Charles River Laboratories, and Quest Diagnostics also experienced declines, with trading volume at 1.5 million, below the 50-day average of 2.1 million.

S&P 500

Illumina

iShares Genomics Immunology and Healthcare ETF

Charles River Laboratorie

Quest Diagnostics

iShares US Healthcare Providers

Labcorp

Illumina Inc. Stock Underperforms Friday When Compared To Competitors

Henry Schein Inc. (HSIC) shares fell 3.21% to $77.60 on Friday, marking its second consecutive day of losses. The stock is now 13.09% below its 52-week high of $89.29. In comparison, competitors Stryker Corp. (SYK), IDEXX Laboratories Inc. (IDXX), and McKesson Corp. (MCK) also experienced declines of 1.60%, 1.70%, and 1.30%, respectively. The overall market was down, with the S&P 500 Index falling 1.33% and the Dow Jones Industrial Average down 0.95%. Trading volume for Henry Schein was 1.7 million, above its 50-day average of 1.3 million.

McKesson

VanEck Pharmaceutical ETF

Invesco Pharmaceuticals ETF

Henry Schein

Stryker

IDEXX Labs

Henry Schein Inc. Stock Underperforms Friday When Compared To Competitors

DYAI

Dyadic International has launched a $4.24 million At-The-Market equity program with Craig-Hallum Capital Group. The agreement allows for the sale of common stock on The Nasdaq Capital Market or other venues, with the company retaining the right to suspend or terminate the program at any time. Craig-Hallum will earn a commission of up to 3.0% on gross proceeds. This program is registered under Dyadic’s effective shelf registration on Form S-3, effective from March 6, 2026.

TradingView

Dyadic

Dyadic International Launches $4.24 Million ATM Equity Program With Craig-Hallum

Direxion S&P Biotech Bear 3X(LABD.US)

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval Push - What's Changed

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV

Is Ardelyx (ARDX) Pricing Reflect Its DCF Upside After Recent Share Price Volatility

Black Diamond (BDI) Signals Growth Despite Near-Term Lumps

16:00 ETLate-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through 2 Years